Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.067
Neutral
RSI(14)
47.044
Neutral
STOCH(KDJ)(9,3,3)
34.923
Sell
ATR(14)
0.247
High Vlolatility
CCI(14)
-17.273
Neutral
Williams %R
55.455
Sell
TRIX(12,20)
0.063
Sell
StochRSI(14)
0.000
Oversold
Oncology Institute Inc
TOI3.340USD
-0.050-1.47%
Market hours （ET）Quotes delayed by 15 min
325.88MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Oncology Institute Inc
Currency: USD Updated: 2025-12-22Key Insights
Oncology Institute Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 48/78 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.50.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Oncology Institute Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
6.500
Target Price
+104.40%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Oncology Institute Inc Highlights
StrengthsRisks
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 55.82% year-on-year.
Undervalued
The company’s latest PE is -5.35, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 39.72M shares, decreasing 16.39% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.55M shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-22The current financial score of Oncology Institute Inc is 7.07, ranking 54/78 in the Healthcare Providers & Services industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 136.56M, representing a year-over-year increase of 36.70%, while its net profit experienced a year-over-year increase of 4.14%.
Score
Financials
5.42
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.37
Operational Efficiency
7.39
Growth Potential
7.95
Shareholder Returns
7.22
Oncology Institute Inc's Company Valuation
Currency: USD Updated: 2025-12-22The current valuation score of Oncology Institute Inc is 7.50, ranking 30/78 in the Healthcare Providers & Services industry. Its current P/E ratio is -5.35, which is -34280.84% below the recent high of 1827.96 and -32.44% above the recent low of -7.08.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 48/78
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-22The current earnings forecast score of Oncology Institute Inc is 8.50, ranking 9/78 in the Healthcare Providers & Services industry. The average price target for Oncology Institute Inc is 6.50, with a high of 8.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
6.500
Target Price
+104.40%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
65
Total
7
Median
9
Average
Company name
Ratings
Analysts
Oncology Institute Inc
TOI
4
CVS Health Corp
CVS
29
HCA Healthcare Inc
HCA
27
Teladoc Health Inc
TDOC
27
Tenet Healthcare Corp
THC
24
Universal Health Services Inc
UHS
22
1
2
3
...
13
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-22The current price momentum score of Oncology Institute Inc is 7.48, ranking 30/78 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 3.97 and the support level at 2.85, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.536
Sell
MA10
3.587
Sell
MA20
3.337
Buy
MA50
3.722
Sell
MA100
3.653
Sell
MA200
3.025
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-22The current institutional shareholding score of Oncology Institute Inc is 3.00, ranking 60/78 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 42.48%, representing a quarter-over-quarter decrease of 4.56%. The largest institutional shareholder is The Vanguard, holding a total of 4.55M shares, representing 4.62% of shares outstanding, with 134.67% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
M33 Growth LLC
OncologyCare Partners LLC
Deerfield Management Company, L.P.
BlackRock Institutional Trust Company, N.A.
CenterBook Partners LP
Balyasny Asset Management LP
Wexford Capital LP
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-22The current risk assessment score of Oncology Institute Inc is 4.38, ranking 50/78 in the Healthcare Providers & Services industry. The company's beta value is 0.18. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.18
VaR
+9.52%
240-Day Maximum Drawdown
+39.12%
240-Day Volatility
+146.67%
Return
Best Daily Return
60 days
+28.90%
120 days
+28.90%
5 years
+38.46%
Worst Daily Return
60 days
-13.26%
120 days
-13.26%
5 years
-35.97%
Sharpe Ratio
60 days
+0.27
120 days
+1.44
5 years
+0.30
Risk Assessment
Maximum Drawdown
240 days
+39.12%
3 years
+94.82%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+24.36
3 years
+0.43
5 years
-0.13
Skewness
240 days
+0.95
3 years
+0.72
5 years
+0.73
Volatility
Realised Volatility
240 days
+146.67%
5 years
--
Standardised True Range
240 days
+7.81%
5 years
+10.89%
Downside Risk-Adjusted Return
120 days
+273.01%
240 days
+273.01%
Maximum Daily Upside Volatility
60 days
+78.68%
Maximum Daily Downside Volatility
60 days
+52.08%
Liquidity
Average Turnover Rate
60 days
+2.25%
120 days
+1.91%
5 years
--
Turnover Deviation
20 days
+98.65%
60 days
+115.89%
120 days
+83.77%
Peer Comparison
Healthcare Providers & Services
Oncology Institute Inc
TOI
6.83 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alignment Healthcare Inc
ALHC
8.79 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Chemed Corp
CHE
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cigna Group
CI
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lifestance Health Group Inc
LFST
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Natera Inc
NTRA
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Oncology Institute Inc?
The TradingKey Stock Score provides a comprehensive assessment of Oncology Institute Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Oncology Institute Inc’s performance and outlook.
How do we generate the financial health score of Oncology Institute Inc?
To generate the financial health score of Oncology Institute Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Oncology Institute Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Oncology Institute Inc.
How do we generate the company valuation score of Oncology Institute Inc?
To generate the company valuation score of Oncology Institute Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Oncology Institute Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Oncology Institute Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Oncology Institute Inc.
How do we generate the earnings forecast score of Oncology Institute Inc?
To calculate the earnings forecast score of Oncology Institute Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Oncology Institute Inc’s future.
How do we generate the price momentum score of Oncology Institute Inc?
When generating the price momentum score for Oncology Institute Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Oncology Institute Inc’s prices. A higher score indicates a more stable short-term price trend for Oncology Institute Inc.
How do we generate the institutional confidence score of Oncology Institute Inc?
To generate the institutional confidence score of Oncology Institute Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Oncology Institute Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Oncology Institute Inc.
How do we generate the risk management score of Oncology Institute Inc?
To assess the risk management score of Oncology Institute Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Oncology Institute Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Oncology Institute Inc.
